Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15864MR)

This product GTTS-WQ15864MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15864MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1609MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ400MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ15597MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ12024MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ7328MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ6584MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ5492MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ1746MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW